TG Therapeutics, Inc. (NASDAQ:TGTX) Given Average Rating of “Moderate Buy” by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $40.67.

A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a report on Monday, November 25th. HC Wainwright reaffirmed a “buy” rating and set a $55.00 price objective on shares of TG Therapeutics in a report on Tuesday, March 4th. Finally, StockNews.com raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 4th.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $38.44 on Wednesday. The company has a fifty day simple moving average of $31.07 and a 200 day simple moving average of $28.57. TG Therapeutics has a 12-month low of $12.93 and a 12-month high of $38.58. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27. The company has a market cap of $6.04 billion, a P/E ratio of -384.36 and a beta of 2.30.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million during the quarter, compared to the consensus estimate of $100.67 million. Sell-side analysts predict that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Sean A. Power sold 11,337 shares of the stock in a transaction that occurred on Friday, January 3rd. The stock was sold at an average price of $30.29, for a total transaction of $343,397.73. Following the completion of the sale, the chief financial officer now owns 670,632 shares of the company’s stock, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 10.50% of the stock is owned by insiders.

Hedge Funds Weigh In On TG Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vermillion Wealth Management Inc. bought a new position in shares of TG Therapeutics during the fourth quarter valued at approximately $30,000. Castleark Management LLC raised its holdings in TG Therapeutics by 25.2% in the fourth quarter. Castleark Management LLC now owns 211,370 shares of the biopharmaceutical company’s stock worth $6,362,000 after purchasing an additional 42,560 shares in the last quarter. Soleus Capital Management L.P. raised its holdings in TG Therapeutics by 5.8% in the fourth quarter. Soleus Capital Management L.P. now owns 2,681,242 shares of the biopharmaceutical company’s stock worth $80,705,000 after purchasing an additional 146,702 shares in the last quarter. Wexford Capital LP bought a new position in TG Therapeutics in the fourth quarter worth $421,000. Finally, Redwood Investments LLC raised its holdings in TG Therapeutics by 0.9% in the fourth quarter. Redwood Investments LLC now owns 94,554 shares of the biopharmaceutical company’s stock worth $2,846,000 after purchasing an additional 886 shares in the last quarter. Institutional investors own 58.58% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.